Patent US1641564A successfully refreshed from Google Patents.
US7297539B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Medium for growing human embryonic stem cells
Assignee: Asterias Biotherapeutics Inc
•
Filing: 2004-06-21
•
Granted: 2007-11-20
•
Expires: 2024-06-21
Abstract
Abstract This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of feeder cells (such as mouse embryonic fibroblasts) to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by components added to the culture environment that support rapid proliferation without differentiation. Effective features are a suitable support structure for the cells, and an effective medium that can be added fresh to the culture without being preconditioned by another cell type. Culturing human embryonic stem cells in fresh medium according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy.
Inventors
- 👤 Ramkumar Mandalam
- 👤 Chunhui Xu
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 03:12
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/10; C12N15/1096; A; A61; A61P; A61P43/00; C12N15/1034; C12N5/00; C12N5/06; C12N5/0602; C12N5/0603; C12N5/0606; C12N5/0618; C12N5/0619; C12N5/0622; C12N11/00; C12N11/02; C12N11/04; C12N2500/00; C12N2500/05; C12N2500/10; C12N2500/20; C12N2500/24; C12N2500/25; C12N2500/90; C12N2500/98; C12N2500/99; C12N2501/00; C12N2501/065; C12N2501/10; C12N2501/105; C12N2501/115; C12N2501/119; C12N2501/125; C12N2501/13; C12N2501/145; C12N2501/155; C12N2501/20; C12N2501/23; C12N2501/2306; C12N2501/235; C12N2501/237; C12N2501/26; C12N2501/998; C12N2502/00; C12N2502/13; C12N2502/99; C12N2503/00; C12N2503/02; C12N2506/00; C12N2506/02; C12N2510/00; C12N2510/04; C12N2533/00; C12N2533/50; C12N2533/90; C12N5/0062; C12N5/0068; C12N5/0075; C12N5/0607; C12N5/0652; C12N5/0662; C12N5/067; C12N5/0671; C12N5/0672; C12N5/0676; C12N5/0678; C12N5/0679; C12N5/068; C12N5/069; C12N5/0692; C12N5/0693; C12N5/0696
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
46 words
A method for proliferating human embryonic: stem (hES) cells, comprising culturing hES cells in the presence of an extracellular matrix in a medium that comprises a fibroblast growth factor at a concentration of at least 40 ng/mL; wherein the culture is essentially free of feeder cells.
Claim 2
Independent Claim
46 words
A method for proliferating human embryonic: stem (hES) cells, comprising culturing hES cells in the presence of an extracellular matrix in a medium that comprises a fibroblast growth factor at a concentration of at least 40 ng/mL; wherein the culture is essentially free of feeder cells.
Claim 3
Dependent Claim
14 words
The method of claim 1 , wherein the medium also contains nucleosides or nucleotides.
Claim 4
Dependent Claim
12 words
The method of claim 1 , wherein the medium also contains insulin.
Claim 5
Dependent Claim
12 words
The method of claim 1 , wherein the medium also contains transferrin.
Claim 6
Dependent Claim
12 words
The method of claim 1 , wherein the medium also contains β-mercaptoethanol.
Claim 7
Dependent Claim
13 words
The method of claim 1 , wherein the medium contains only human protein.
Claim 8
Dependent Claim
17 words
The method of claim 1 , wherein the fibroblast growth factor is basic fibroblast growth factor (bFGF).
Claim 9
Dependent Claim
13 words
The method of claim 7 , wherein the bFGF is recombinant human bFGF.
Claim 10
Dependent Claim
14 words
The method of claim 1 , wherein the medium also contains stem cell factor.
Claim 11
Dependent Claim
13 words
The method of claim 1 , wherein the medium also contains Flt3 ligand.
Claim 12
Dependent Claim
11 words
The method of claim 1 , wherein the medium is non-conditioned.
Claim 13
Dependent Claim
23 words
The method of claim 1 , wherein the extracellular matrix comprises reconstituted basement membrane from Engelbreth-Holm-Swarm tumor cells, laminin, fibronectin, proteoglycan, or entactin.
References Cited (Backward Citations)
US5104795A
Cited
US5166065A
Cited
US5234809A
Cited
US5464764A
Cited
US5981165A
Cited
US5332672A
Cited
US5789158A
Cited
US5840484A
Cited
US5672499A
Cited
WO1994007997A1
Cited
US5453357A
Cited
EP0695351B1
Cited
US5523226A
Cited
US5942435A
Cited
US5405772A
Cited
US5643761A
Cited
US5591625A
Cited
US5639618A
Cited
US5583016A
Cited
US5914268A
Cited
WO1996017627A2
Cited
US6200806B1
Cited
US5843780A
Cited
US6261556B1
Cited
US5922597A
Cited
WO1997021802A1
Cited
WO1997028253A1
Cited
WO1997030151A1
Cited
US6040180A
Cited
WO1997047734A1
Cited
WO1998000540A1
Cited
US5856136A
Cited
WO1998030678A1
Cited
WO1998030679A1
Cited
WO1998043679A1
Cited
WO1999001552A1
Cited
WO1999010535A1
Cited
US5968829A
Cited
WO1999020741A1
Cited
WO1999042122A1
Cited
WO1999043785A1
Cited
US6875607B1
Cited
US20050148070A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2010-11-19 | 2011-05-21 | 2011-11-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2014-11-19 | 2015-05-21 | 2015-11-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2018-11-19 | 2019-05-21 | 2019-11-20 | $7700.00 | Window Closed / Lapsed |